SUBSCRIBE
SUBSCRIBE

Phase 2

Courtesy of Sundry Photography/Getty Images
Drug Development
Early Data from Gilead’s Compassionate Use of Remdesivir for COVID-19 Looks Promising
The study of the 53 patients in the U.S., Europe and Canada who required respiratory support showed that about two-thirds benefited from the drug.
April 13, 2020
 · 
3 min read
 · 
Mark Terry
BioCapital
Clinical Catch-Up: April 6-10
It was a very busy week for clinical trial news. Here’s a look.
April 10, 2020
 · 
12 min read
 · 
Mark Terry
Physician holds up hand in a stop sign signal_Shut
Drug Development
COVID-19 Continues to Impact Enrollment and Recruitment of Clinical Trial Patients
As COVID-19 has swept across the world, companies have had to make significant adjustments to the way business is conducted in a global economy. It has impacted all types of operations, including clinical trials.
April 10, 2020
 · 
4 min read
 · 
Alex Keown
Drug Development
Biopharma Update on the Novel Coronavirus: April 10
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 10, 2020.
April 10, 2020
 · 
7 min read
 · 
BioSpace Editorial Staff
Drug Development
China’s CanSino Prepares to Advance COVID-19 Vaccine Candidate into Phase II
China’s CanSino Biologics is advancing its COVID-19 vaccine candidate into Phase II, putting the company ahead of others in the race against the novel coronavirus.
April 10, 2020
 · 
2 min read
 · 
Alex Keown
Drug Development
Biopharma Update on the Novel Coronavirus: April 9
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 9, 2020.
April 9, 2020
 · 
9 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: April 8
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 8, 2020.
April 8, 2020
 · 
7 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: April 7
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 7, 2020.
April 7, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Update on the Novel Coronavirus: April 6
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 6, 2020.
April 6, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
Drug Development
Axon’s Tau Vaccine Shows Promise in Phase II Alzheimer’s Study
During a presentation at the AAT-AD/PD 2020 conference, Axon said AADvac1 showed a disease-modifying effect on Alzheimer’s disease.
April 3, 2020
 · 
2 min read
 · 
Alex Keown
Load More
PRESS RELEASES
Press Releases
Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer
February 26, 2026
 · 
2 min read
Press Releases
Aramis Biotechnologies announces the achievement of an important milestone with the start of a Phase 1/2 clinical trial of its vaccine in development against seasonal influenza in 728 participants
February 26, 2026
 · 
2 min read
Press Releases
New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors
February 26, 2026
 · 
7 min read
Press Releases
AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder
February 26, 2026
 · 
10 min read
Press Releases
Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026
February 26, 2026
 · 
6 min read
Press Releases
Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell
February 26, 2026
 · 
7 min read
Press Releases
Mahzi Therapeutics Announces First Patient Dosed in Phase 1/2 UNITE Study of MZ-1866 for Pitt Hopkins Syndrome
February 26, 2026
 · 
4 min read
Press Releases
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026
February 25, 2026
 · 
11 min read
Press Releases
Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA
February 25, 2026
 · 
6 min read
Press Releases
Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor)
February 25, 2026
 · 
8 min read
Press Releases
FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update
February 25, 2026
 · 
7 min read
Press Releases
HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES
February 25, 2026
 · 
6 min read
Press Releases
Verdiva Bio Announces Completion of Enrollment for EVOLVE-2 Phase 2b Study of VRB-101, a Potential Once-Weekly Oral GLP-1 Peptide Analog in Individuals with Obesity
February 25, 2026
 · 
3 min read
Press Releases
AdvanCell Showcases Novel TheraPb Phase 2 Study Design of ADVC001 for the Treatment of Metastatic Prostate Cancer at ASCO GU Symposium 2026
February 24, 2026
 · 
5 min read
Press Releases
Vico Therapeutics Announces Patient Dosing in Twice-Annual Regimen of VO659 in Phase 1/2 Trial in Huntington’s Disease, Spinocerebellar Ataxia Type 3 and Type 1
February 24, 2026
 · 
3 min read
Press Releases
AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics’ Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01)
February 24, 2026
 · 
4 min read
Press Releases
Abcuro Announces Topline Results from the MUSCLE Study of Ulviprubart in Patients with Inclusion Body Myositis
February 24, 2026
 · 
3 min read
Press Releases
OrthoTrophix Announces Early Completion of Enrollment in Phase 2b Trial of TPX-100 in Knee Osteoarthritis
February 24, 2026
 · 
3 min read
Press Releases
Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement
February 24, 2026
 · 
9 min read
Press Releases
ORYZON Receives European Medicines Agency Approval to Initiate a Phase II Study of iadademstat in Essential Thrombocythemia
February 24, 2026
 · 
10 min read
Load More